TY  - CHAP
M1  - Book, Section
TI  - Disorders of Potassium and Magnesium Homeostasis
A1  - Flurie, Rachel W.
A1  - Brophy, Donald F.
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
PY  - 2017
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - Content  UpdateMay  24,  2018Sodium  Zirconium  Cyclosilicate  (Lokelma)  for  Treatment  of  Hyperkalemia:  In  May  2018,  the  U.S.  Food  and  Drug  Administration  approved  sodium  zirconium  cyclosilicate  for  treatment  of  hyperkalemia  in  adults.  The  drug  is  a  cation  exchange  resin  that  exchanges  potassium  for  sodium  and  hydrogen  in  the  gut  lumen,  thereby  increasing  fecal  potassium  excretion;  this  reduces  free  potassium  concentrations  and  lowers  serum  potassium  levels.  It  represents  the  third  cation  exchange  resin  available  for  commercial  use  in  addition  to  sodium  polystyrene  sulfonate  (Kayexalate)  and  patiromer  sorbitex  calcium  (Veltassa).  Healthcare  providers  should  be  knowledgeable  about  each  drug's  efficacy,  dosing,  adverse  effects,  precautions,  drug  interactions,  and  cost  prior  to  clinical  use.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/24
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1153854970
ER  -